Literature DB >> 20661556

Incidental pituitary uptake on whole-body 18F-FDG PET/CT: a multicentre study.

Shin Young Jeong1, Sang-Woo Lee, Hui Joong Lee, Sungmin Kang, Ji-Hyoung Seo, Kyung Ah Chun, Ihn Ho Cho, Kyung Sook Won, Seok Kil Zeon, Byeong-Cheol Ahn, Jaetae Lee.   

Abstract

PURPOSE: The purpose of this study was to determine the incidence of incidental pituitary uptake on whole-body 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and to investigate its clinical significance.
METHODS: The files of 40,967 patients who underwent whole-body FDG PET/CT were retrospectively reviewed. Quantification of pituitary metabolic activity was obtained by using the maximum standardized uptake value (SUVmax). Hormone assays and pituitary MRIs were performed to assess pituitary lesions.
RESULTS: Focally increased pituitary FDG uptake on PET/CT was found in 30 of 40,967 patients, accounting for an incidence of 0.073%. The mean SUVmax of 30 patients was 8.9±6.6 (range: 3.2-32.6). Histological diagnosis was obtained in three patients and included two growth hormone-secreting adenomas and one non-functioning adenoma. Hormone assays were performed on serum samples from 11 patients, 2 of whom were shown to have hypersecretion of pituitary hormone. MRI was performed on 19 patients. Abnormal MRI findings suggesting a pituitary mass were found in 18 of 19 cases (94.7%). The mean SUV(max) calculated without correction for partial volume effect for macroadenomas was significantly higher than the SUVmax for microadenomas (11.5±8.4 vs 4.8±1.3; p<0.05). There were no cases diagnosed with metastasis to the pituitary gland during clinical follow-up.
CONCLUSION: Incidental pituitary FDG uptake was a very rare finding. Cases with incidental pituitary FDG uptake were diagnosed primarily with clinically non-functioning adenomas, and there were also a few functioning adenomas. Further evaluations, including hormone assays and pituitary MRI, are warranted when pituitary uptake is found on FDG PET/CT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20661556     DOI: 10.1007/s00259-010-1571-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  29 in total

1.  [Positron emission tomography (PET) of an invasive ACTH-producing pituitary adenoma].

Authors:  T Sasajima; K Mineura; M Kowada; F Shishido; K Uemura
Journal:  Rinsho Hoshasen       Date:  1990-03

2.  Combined PET/CT Imaging in Oncology. Impact on Patient Management.

Authors:  P G. Kluetz; C C. Meltzer; V L. Villemagne; P E. Kinahan; S Chander; M A. Martinelli; D W. Townsend
Journal:  Clin Positron Imaging       Date:  2000-11

3.  Serendipitous detection of Cushing's disease by FDG positron emission tomography and a review of the literature.

Authors:  Tsuyoshi Komori; William H Martin; Alan L Graber; Dominique Delbeke
Journal:  Clin Nucl Med       Date:  2002-03       Impact factor: 7.794

Review 4.  Incidentalomas. A disease of modern technology.

Authors:  R M Chidiac; D C Aron
Journal:  Endocrinol Metab Clin North Am       Date:  1997-03       Impact factor: 4.741

5.  18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours.

Authors:  J Kumar; M Spring; P V Carroll; S F Barrington; J K Powrie
Journal:  Clin Endocrinol (Oxf)       Date:  2006-04       Impact factor: 3.478

6.  Pituitary microadenomas: early enhancement with dynamic CT--implications of arterial blood supply and potential importance.

Authors:  J F Bonneville; F Cattin; W Gorczyca; J Hardy
Journal:  Radiology       Date:  1993-06       Impact factor: 11.105

7.  The diagnostic value of fused positron emission tomography/computed tomography in the localization of adrenocorticotropin-secreting pituitary adenoma in Cushing's disease.

Authors:  Ali S Alzahrani; Rafif Farhat; Abdullah Al-Arifi; Nora Al-Kahtani; Imad Kanaan; Mohei Abouzied
Journal:  Pituitary       Date:  2009-04-22       Impact factor: 4.107

8.  Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging.

Authors:  Wengen Chen; Molly Parsons; Drew A Torigian; Hongming Zhuang; Abass Alavi
Journal:  Nucl Med Commun       Date:  2009-03       Impact factor: 1.690

9.  The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome.

Authors:  Karel Pacak; Ioannis Ilias; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

10.  Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison.

Authors:  Harry Agress; Benjamin Z Cooper
Journal:  Radiology       Date:  2003-12-29       Impact factor: 11.105

View more
  16 in total

1.  Evolution of (18)FDG pituitary uptake after medical control of acromegaly.

Authors:  Jean-Christophe Maiza; Cedric Revel
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

2.  Acromegaly revealed by 18FDG-PET/CT in a plasmocytoma patient.

Authors:  Jean-Christophe Maiza; Patricia Zunic; Cedric Revel; Stephane Schneebeli
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

3.  Analysis of 18F-fluorodeoxyglucose positron emission tomography findings in patients with pituitary lesions.

Authors:  Hannah Seok; Eun Young Lee; Eun Yeong Choe; Woo In Yang; Joo Young Kim; Dong Yeob Shin; Ho Jin Cho; Tae Sung Kim; Mi Jin Yun; Jong Doo Lee; Eun Jig Lee; Sung-Kil Lim; Yumie Rhee
Journal:  Korean J Intern Med       Date:  2012-12-28       Impact factor: 2.884

Review 4.  Endocrine incidentalomas--challenges imposed by incidentally discovered lesions.

Authors:  Dimitra A Vassiliadi; Stylianos Tsagarakis
Journal:  Nat Rev Endocrinol       Date:  2011-06-28       Impact factor: 43.330

5.  Pituitary lymphoma developing within pituitary adenoma.

Authors:  Ken Morita; Fumihiko Nakamura; Yasuhiko Kamikubo; Naoaki Mizuno; Masashi Miyauchi; Go Yamamoto; Yasuhito Nannya; Motoshi Ichikawa; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2012-04-21       Impact factor: 2.490

6.  High-resolution(18)F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease.

Authors:  Prashant Chittiboina; Blake K Montgomery; Corina Millo; Peter Herscovitch; Russell R Lonser
Journal:  J Neurosurg       Date:  2014-12-05       Impact factor: 5.115

7.  CRH stimulation improves 18F-FDG-PET detection of pituitary adenomas in Cushing's disease.

Authors:  Jacqueline Boyle; Nicholas J Patronas; James Smirniotopoulos; Peter Herscovitch; William Dieckman; Corina Millo; Dragan Maric; Grégoire P Chatain; Christina Piper Hayes; Sarah Benzo; Gretchen Scott; Nancy Edwards; Abhik Ray Chaudhury; Maya B Lodish; Susmeeta Sharma; Lynnette K Nieman; Constantine A Stratakis; Russell R Lonser; Prashant Chittiboina
Journal:  Endocrine       Date:  2019-05-06       Impact factor: 3.633

Review 8.  60 Years of Achievements by KSNM in Neuroimaging Research.

Authors:  Jae Seung Kim; Hye Joo Son; Minyoung Oh; Dong Yun Lee; Hae Won Kim; Jungsu Oh
Journal:  Nucl Med Mol Imaging       Date:  2022-01-15

9.  Corticotropin releasing hormone can selectively stimulate glucose uptake in corticotropinoma via glucose transporter 1.

Authors:  Jie Lu; Blake K Montgomery; Grégoire P Chatain; Alejandro Bugarini; Qi Zhang; Xiang Wang; Nancy A Edwards; Abhik Ray-Chaudhury; Marsha J Merrill; Russell R Lonser; Prashant Chittiboina
Journal:  Mol Cell Endocrinol       Date:  2017-10-03       Impact factor: 4.102

10.  Clinically Occult Pituitary Adenoma Can Appear as a Hypermetabolic Lesion on Whole Body FDG PET Imaging in a Patient with Lymphoma.

Authors:  Inanç Karapolat; Güray Oncel; Kamil Kumanlıoğlu
Journal:  Mol Imaging Radionucl Ther       Date:  2013-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.